Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
6.69
-0.06 (-0.89%)
At close: Apr 28, 2026, 4:00 PM EDT
6.70
+0.01 (0.15%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Profound Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Profound Medical stock has a target of 12, which predicts an increase of 79.37% from the current stock price of 6.69.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 7, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Profound Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +79.37% | Jan 7, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $17 → $11 | Strong Buy | Maintains | $17 → $11 | +64.42% | Apr 23, 2025 |
| Stifel | Stifel | Hold → Strong Buy Upgrades $9 → $12 | Hold → Strong Buy | Upgrades | $9 → $12 | +79.37% | Jul 16, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +61.43% | Mar 11, 2024 |
| Stifel | Stifel | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +34.53% | Mar 8, 2024 |
Financial Forecast
Revenue This Year
30.97M
from 16.10M
Increased by 92.40%
Revenue Next Year
50.83M
from 30.97M
Increased by 64.10%
EPS This Year
-0.90
from -1.41
EPS Next Year
-0.68
from -0.90
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 33.2M | 55.4M | ||||||
| Avg | 31.0M | 50.8M | ||||||
| Low | 29.4M | 46.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 106.1% | 79.0% | ||||||
| Avg | 92.4% | 64.1% | ||||||
| Low | 82.6% | 50.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.83 | -0.58 | ||||||
| Avg | -0.90 | -0.68 | ||||||
| Low | -0.99 | -0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.